The Arc Institute unveiled 'Germinal', an AI-driven platform combining AlphaFold-Multimer gradients and antibody language models to design epitope-targeted antibodies with reduced experimental burden. Concurrently, CRISPR screens conducted by Mass General Brigham and the Broad Institute identified gene knockout strategies enhancing CAR T cell therapies for multiple myeloma. These advances exemplify how AI and genetic screening synergistically propel immunotherapy innovation by enabling targeted molecular design and functional optimization of immune cells.